Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF)...
                   
finanznachrichten.de
04-Sep-2008 29 related
        

Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers [marketed as Remicade® (infliximab), Enbrel® (etanercept), Humira® (adalimumab) and Cimzia® (certolizumab pegol)]. AMGEN AND WYETH... [read full story]                    

Add Comment
There are also 29 related articles
View all news articles about*:
Ambulatory Amgen Arthritis Biopharmaceuticals Bones Care Child Childhood Diseases Disorders Health Joints Juvenile Medicines Patients Pharmaceuticals Remedies Research Rheumatism Rheumatoid Wyeth
*Newstin tag cloud displays all featured persons, associated organisations, related topics, regions and companies

View other selected articles:

                   

::: Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for...

pharmiweb.co.uk
30 mins ago 4 related
        

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. announced today that the U.S. Food and Drug Administration has issued a second complete response letter regarding the supplemental biologics license application...

add comment

Ireland's financial regulator chief to retire

tiscali.co.uk
1 hr ago 1 related
        

DUBLIN (Reuters) - Ireland's financial regulator chief Patrick Neary said on Friday he would retire at the end of January after an internal committee completed its findings into a loan scandal at Anglo Irish Bank The niche...

add comment
                   
dailymail.co.uk: Breast cancer cells dailymail.co.uk

MAIL COMMENT: Medical science must understand its limits

dailymail.co.uk
30 mins ago 2 related
        

In a perfect world, no couple wishing to raise a family would face the torture of knowing there is a high chance that any daughter they might have would be born with an 80 per cent chance of developing breast cancer. More from...

add comment

::: Array BioPharma Initiates Phase 1 Clinical Trial for MEK Inhibitor ARRY-300

pharmiweb.co.uk
31 mins ago 6 related
        

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) has initiated dosing in healthy volunteers in a Phase 1 clinical trial with ARRY-300, a targeted small molecule MEK inhibitor. “We believe ARRY-300 is a...

add comment